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Background. The neuropathology of Parkinson’s disease (PD) includes loss of dopaminergic neurons in the substantia nigra,
nitrated a-synuclein (N-a-Syn) enriched intraneuronal inclusions or Lewy bodies and neuroinflammation. While the
contribution of innate microglial inflammatory activities to disease are known, evidence for how adaptive immune
mechanisms may affect the course of PD remains obscure. We reasoned that PD-associated oxidative protein modifications
create novel antigenic epitopes capable of peripheral adaptive T cell responses that could affect nigrostriatal degeneration.
Methods and Findings. Nitrotyrosine (NT)-modified a-Syn was detected readily in cervical lymph nodes (CLN) from 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxicated mice. Antigen-presenting cells within the CLN showed increased
surface expression of major histocompatibility complex class II, initiating the molecular machinery necessary for efficient
antigen presentation. MPTP-treated mice produced antibodies to native and nitrated a-Syn. Mice immunized with the NT-
modified C-terminal tail fragment of a-Syn, but not native protein, generated robust T cell proliferative and pro-inflammatory
secretory responses specific only for the modified antigen. T cells generated against the nitrated epitope do not respond to the
unmodified protein. Mice deficient in T and B lymphocytes were resistant to MPTP-induced neurodegeneration. Transfer of T
cells from mice immunized with N-a-Syn led to a robust neuroinflammatory response with accelerated dopaminergic cell loss.
Conclusions. These data show that NT modifications within a-Syn, can bypass or break immunological tolerance and activate
peripheral leukocytes in draining lymphoid tissue. A novel mechanism for disease is made in that NT modifications in a-Syn
induce adaptive immune responses that exacerbate PD pathobiology. These results have implications for both the
pathogenesis and treatment of this disabling neurodegenerative disease.
Citation: Benner EJ, Banerjee R, Reynolds AD, Sherman S, Pisarev VM, et al (2008) Nitrated a–Synuclein Immunity Accelerates Degeneration of Nigral
Dopaminergic Neurons. PLoS ONE 3(1): e1376. doi:10.1371/journal.pone.0001376
INTRODUCTION
Parkinson’s disease(PD) is a common progressive neurodegenerative
disease clinically characterized by resting tremor, muscle rigidity,
bradykinesia, and postural instability [1]. PD is sporadic and of
unknown cause although host genetics, environmental cues, aging,
impaired energy metabolism and oxidative stress are linked to
diseaseonsetandprogression[2].Pathologically,PDischaracterized
by degeneration of dopaminergic cell bodies in the substantia nigra
pars compacta (SNpc) and their associated caudate projections [1].
Nonetheless, the pathological hallmark of PD is cytoplasmic
inclusions of fibrillar, misfolded proteins called Lewy bodies
composed principally of a-synuclein (a-Syn) [3].
a-Syn is a 140-amino acid (aa), natively unfolded, soluble
protein that is localized in the pre-synaptic terminals of neurons of
the central nervous system (CNS), where it interacts with and may
regulate synaptic vesicles [3,4,5,6,7,8]. Three missense mutations
(A53T, A30P and E46K) in the gene encoding a-Syn are linked to
dominantly inherited PD [9,10,11]. Moreover, multiplication of
the wild-type (WT) gene has also been linked to PD, suggesting
that the level of a-Syn is an important pathogenic factor [12,13].
Such familial cases are rare and in sporadic PD, there is no genetic
aberration of a-Syn. However, it has been proposed that post-
translational modifications such as nitration enhances WT a-Syn
propensity to aggregate [14,15,16,17]. Oxidized and aggregated a-
Syn, when released from dying neurons, may stimulate scavenger
receptors on microglia resulting in their sustained activation and
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microglia generate nitric oxide and superoxide that rapidly react
to form peroxynitrite [21] which can then traverse cell membranes
resulting in 3-nitrotyrosine (NT) formation, DNA damage,
mitochondrial inhibition, or lipid peroxidation [22].
We now propose that modified ‘‘self’’ epitopes as neo-epitopes,
including NT modifications within a-Syn, can bypass or possibly
break immunological tolerance [23,24,25,26,27,28,29] and activate
peripheral leukocytes in draining lymphoid tissue. In keeping with
this, NT-modifications incorporated into self-peptides were sufficient
to evade immunological tolerance as was previously reported [30].
The recruitment of activated T cells, specific for disease-associated
protein modifications in a-Syn, may, in turn, promote a toxic
microglial phenotype. The role of the adaptive immune system is
becoming increasingly important in ‘‘non-autoimmune’’ diseases of
the CNS [31]. Research in traumatic and neurodegenerative models
have suggested a neuroprotective role for T and B cells within the
CNS and that manipulation of the peripheral immune system can
affect neurodegeneration [32]. Our own studies demonstrated that
immunization of mice with glatiramer acetate generate T cells that
recognize myelin basic protein (TMBP), secrete interleukin (IL)-10,
IL-4,andtransforminggrowthfactor(TGF)-b,andconferprotection
against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-in-
duced neurodegeneration presumably by suppression of microglial
activation [33]. Antibodies generated through active immunization
of human a-Syn transgenic mice with purified human a-Syn protein
reduced a-Syn aggregation in cell bodies and terminals, and was
associated with protection of dopaminergic nerve terminals [34].
The conclusions were that anti-a-Syn antibodies target the
aggregated protein to lysosomal pathways for degradation and that
the strategy could be applied for treatment of human disease. That
work was conducted however in an animal model of PD that lacks a
neuroinflammatory component. As such, the study did not address
thecellulararmoftheimmunesystem,whichlikelyrequirescytokine
and chemokine gradients for efficient cellentry into diseased regions.
Nevertheless, the work of Masliah et al., 2005 supports the potential
importance for adaptive immunity and for immune-based strategies
for the treatment of PD. Certainly, research activities into the
potential use of a-Syn as an immunogen will require further study.
Here, we report that NT-modified CNS antigens drain to the
deep cervical lymph nodes (CLN) of mice following exposure to
MPTP. Moreover, antigen-presenting cells (APC) within CLN
increase surface expression of major histocompatibility complex
(MHC) class II, initiating the molecular machinery necessary for
efficient antigen presentation. The differential outcome on the
susceptibility to MPTP-induced dopaminergic neurodegeneration
amongst WT and severe combined immunodeficient (SCID) mice
suggest a functional link of the adaptive immune system to MPTP-
induced neurotoxicity. We further demonstrate in mice of two
disparate haplotypes, that adoptive transfer of T cells from
syngeneic WT donors immunized with nitrated a-Syn (N-a-Syn)
prolongs MPTP-induced dopaminergic neuronal loss and hence
warrants caution against the use of N-a-Syn or self-proteins that
are prone to nitrate modifications for vaccine-based PD therapies.
MATERIALS AND METHODS
Animals
Male 6–7 week old, WT C57BL/6J (stock 000664, denoted as B6)
(H-2
b), B6.CB17-Prkdc
scid/SzJ (stock 001913, herein denoted as
SCID) (H-2
b) and B10.BR-H2
k H2-T18
a/SgSnJ (stock 000465,
herein denoted as B10.BR) (H-2
k) mice were purchased from
Jackson Laboratories (Bar Harbor, ME). All animal procedures
were in accordance with National Institutes of Health (NIH)
guidelines and approved by the Institutional Animal Care and Use
Committee (IACUC) of the University of Nebraska Medical
Center (UNMC).
MPTP Intoxication
For chronic intoxication, B6 mice received 5 intraperitoneal (i.p.)
injections at 24 hr intervals for 5 days of either vehicle (PBS,
10 ml/kg) or MPTP-HCl (30 mg/kg of free base in PBS) (Sigma-
Aldrich, St. Louis, MO). For acute intoxication, mice received 4
i.p. injections, one every 2 hr, of either vehicle (PBS, 10 ml/kg) or
MPTP-HCl (18 mg/kg of free base in PBS for B10.BR mice, 14 or
18 mg/kg for B6 mice). At selected time points following MPTP
intoxication, mice were sacrificed and brains processed for
subsequent analyses. MPTP handling and safety measures were
in accordance with published guidelines [35].
Immunohistochemistry
At the time points indicated following MPTP intoxication, mice
were transcardially perfused with 4% paraformaldehyde (PFA) in
0.1 M PBS using 0.9% saline as vascular rinse. Brains were post-
fixed in 4% PFA overnight, kept in 30% sucrose for 2 days, snap
frozen, embedded in OCT compound, and 30 mm sections cut on
a cryostat (CM1900, Leica, Bannockburn, IL). The sections were
collected in PBS and processed free-floating. Primary antibodies
used for immunohistochemistry includes rabbit anti-TH antibody
(1:2000; Calbiochem/EMD Biosciences, Inc., San Diego, CA), rat
anti-mouse CD11b or Mac-1 (1:1,000; Serotec, Raleigh, NC), rat
anti-CD3 (1:800; BD Pharmingen, San Diego, CA,), rat anti-CD4
(BD Pharmingen), and rat anti-CD8 (BD Pharmingen). Immuno-
staining was visualized using diaminobenzidine (Sigma-Aldrich) as
the chromogen and mounted on slides. TH, CD3-, CD4- and
CD8-immunostained brain sections were counterstained with
thionin (Sigma-Aldrich) as previously described [33,36]. Fluoro-
Jade C (Chemicon International, Inc., Temecula, CA) was used to
stain degenerating neurons [37] and was detected as green
fluorescence by fluorescence microscopy with FITC filter (Eclipse
E800, Nikon, Inc., Melville, NY).
Stereology of TH-Positive Neurons
Total numbers of Nissl- and TH-stained neurons throughout the
entire SNpc were counted stereologically in a blinded fashion with
Stereo Investigator software (MicroBrightfield, Williston, VT)
using the Optical Fractionator probe module as previously
described [33].
Cloning a-Syn and 4YSyn
Total RNA from adult C57BL/6 mouse brain was extracted using
TRIzol reagent (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instructions. The full-length mouse a-Syn gene
(504 bp) and 120 bp length encoding the C-terminal portion
(4YSyn) was amplified by reverse transcriptase-polymerase chain
reaction (RT-PCR) using Platinum Taq DNA Polymerase High
Fidelity (Invitrogen). The 59 primer was designed to introduce a
Nde1 site at position 1. This fragment was blunt cloned into the
pZero-1 (Invitrogen) Eco RV site using standard cloning
procedures. Transformed cells were plated on low salt agar
containing Zeocyn and 3 mM IPTG. Colonies were screened
using colony PCR with a-Syn primers. Colonies containing the
full-length mouse a-Syn gene or the 39 fragment encoding 4YSyn
were grown overnight and plasmid DNA was isolated using
standard mini-prep (Invitrogen). The gene was digested out of
pZero with Nde1 and Xho1 and subcloned into the Nde1 and
Xho1 sites in the pET-28a prokaryotic expression vector using
Immunity and Neurodegeneration
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plasmids were submitted to the UNMC core facility for sequence
confirmation. Plasmids containing the complete sequence were
transformed into BL-21 E. coli cells for expression. Frozen glycerol
stocks were maintained at 280uC.
4YSyn Expression
Glycerol stocks were streaked on Luria-Bertani (LB) agar plate
containing 30 mg/ml kanamycin. A single colony was inoculated
into LB broth containing 30 mg/ml kanamycin, grown for 8 hrs,
and stored at 4uC until the following day. The starter culture was
diluted 1:100 into fresh liquid medium containing 30 mg/ml
kanamycin and allowed to grow to an OD600=0.6. Expression of
recombinant protein was induced by the addition of 3 mM IPTG
with continued incubation for 3 hrs at 37uC. Following induction,
cells were centrifuged, weighed, and stored at 280uC until
purification protocol was resumed. .90% of detectable 4YSyn
was found in the soluble fraction.
Protein Purification and Nitration
Cell lysis was performed with Bug Buster reagent (Novagen/EMD
Biosciences, Inc., San Diego, CA) at 5 ml/g cells with addition of
EDTA-free protease inhibitor cocktail (Calbiochem). Benzonase
nuclease (Novagen) was added to reduce viscosity during lysis
following manufacturer’s instructions. Insoluble cell debris was
removed by centrifugation at 16,0006g for 20 min at 4uC. The
soluble fraction was directly subjected to column affinity
chromatography and was carried out in the following steps: His-
tagged protein was bound to Ni-NTA His Bind Resin (Novagen) in
Bug Buster reagent with the addition of imidazole (10 mM). The
column was washed first with 50 mM NaH2PO4/300 mM NaCl/
20mM imidazole, pH 8.0 and then with 50 mM NaH2PO4/
300 mM NaCl/35mM imidazole, pH 8.0. Elution was carried out
50 mM NaH2PO4/300 mM NaCl/250 mM imidazole pH 8.0.
Samples were separated by SDS-PAGE and stained with Brilliant
Blue G-Colloidal Coomassie stain (Invitrogen) to confirm purity of
the eluted fraction. Full-length a-Syn and 4YSyn were visualized
by silver stain (Silver Xpress, Invitrogen). Purified full-length a-Syn
was dialyzed in 50 mM NaH2PO4 buffer. Thrombin cleavage was
carried out using biotinylated thrombin cleavage capture kit
(Novagen) following manufacturer’s instructions. Cleaved His-tags
were removed with Ni-NTA resin. His-tag free full-length a-Syn
and His-tagged 4YSyn (unable to remove the His-tag) were
dialyzed against water for 24–48 hrs with multiple water changes,
lyophilized, and weighed. Endotoxin was removed by polymyxin B
agarose beads following manufacturer’s instructions (Sigma-
Aldrich) and tested for residual endotoxin by Limulus amebocyte
lysate (LAL) assay (E-Toxate, Sigma-Aldrich). Recombinant a-
Syn-derived proteins were endotoxin-free as all batches of purified
proteins utilized tested below the limit of detection for endotoxin
by LAL (,0.05 endotoxin units, EU).
Lyophilized protein was resuspended (2 mg protein/ml) in
50 mM NaH2PO4 buffer containing 5 mM FeCl3 as a Lewis acid.
Peroxynitrite (Upstate Biotechnology, Inc. Lake Placid, NY) was
added dropwise to protein to achieve a 5 M excess while
vigorously mixing the reaction mixture. Nitrated protein was
dialyzed against water for 48 hrs using multiple water exchanges,
lyophilized, and stored at 280uC.
MALDI-TOF Mass Spectrometry
MALDI-TOF mass spectrometric analysis was performed using a
Voyager DE Pro mass analyzer (Applied Biosystems, Framing-
ham, MA), which was externally calibrated prior to each assay.
Data acquisition was performed using 500 laser shots. The MS
scan range was set from 500 to 20,000 m/z. Saturated a-
cyanohydroxycinnamic acid (Sigma-Aldrich) was used as matrix
in these assays and samples were manually spotted onto MALDI
targets.
Enzyme-Linked Immunosorbent Assay (ELISA)
Individual wells of Immunolon II ELISA plates (Thermo Electron
Corp., Waltham, MA) were coated with 100 ml/well of native
4YSyn or N-4YSyn at 1 mg/ml PBS, pH 8.5. Plates were
incubated for 2 hrs at 37uC and washed with 0.5% Tween20/
PBS, pH 7.2 (PBS-T). Nonspecific binding was blocked by the
addition of 1% bovine serum albumin in PBS, pH 7.2 (PBS-BSA)
and incubation at 37uC for 1 hr. Plates were washed with PBS-T,
100 ml of 2-fold serial dilutions (from an initial 1:50 dilution in
PBS-BSA) of serum samples from MPTP- or PBS-treated mice
were added to each well, and incubated at 37uC for 1 hr. Plates
were washed with PBS-T and 100 ml/well of a 1:5000 dilution of
horseradish peroxidase (HRP)-conjugated anti-mouse IgG (South-
ernBiotech, Birmingham, AL) was added. Plates were incubated at
37uC for 1 hr, washed with PBS-T, and reacted with 0.012%
H2O2 and 2.2 mM o-phenylenediamine dihydrochloride (Sigma-
Aldrich) in 100 ml of 0.1 M phosphate-citrate buffer, pH 5.0. The
reaction was stopped with the addition of 2 N H2SO4, read at
490 nm on a microplate reader (Vmax Kinetic Microplate
Reader, Molecular Devices Corporation, Sunnyvale, CA), and
acquired data analyzed with interfacing SoftMax Pro software
(Molecular Devices). Serum IgG concentrations were quantified
from a standard curve prepared from known concentrations of
mouse IgG (SouthernBiotech).
Immunization and Immune Cell Adoptive Transfers
B10.BR (H-2
K) mice were immunized with PBS, 50 mg of 4YSyn
or N-4YSyn emulsified in an equal volume of CFA containing
1 mg/ml Mycobacterium tuberculosis (Sigma-Aldrich). B6 (H-2
b) mice
were immunized with PBS, 10 mg of 4YSyn or N-4YSyn with or
without CFA. While immunization with adjuvant were adminis-
tered subcutaneous (s.c.) on either side of the tail base, s.c.
injections without adjuvant were given at 5 different sites.
Fourteen days after primary immunization, mice were boosted
with their respective antigens. CFA recipient mice were boosted
with their respective antigens emulsified in IFA (Sigma-Aldrich).
Five days following their final immunizations, donor mice were
sacrificed and single cell suspensions were prepared from the
spleen and draining lymph nodes after lysing red blood cells with
ammonium chloride-potassium (ACK) lysis buffer (0.15M NH4Cl,
10 mM KHCO3, 0.1 mM Na2EDTA, pH7.2). T cells were
enriched by using the PAN T cell isolation kit (Miltenyi Biotec,
Auburn, CA) and by depletion of magnetically labeled cells
employing AutoMACS (Miltenyi Biotec). Twelve hrs post-MPTP
intoxication, both B10.BR and B6 mice received intravenous (i.v.)
injections of 5610
7 spleen cells (SPC) in 0.25 ml of Hanks’
balanced salt solution (HBSS). B10.BR mice also received 2.5610
7
purified T cells. SCID mice were reconstituted with i.v. injections
of 8610
7 unfractionated SPC populations from WT B6 mice.
RCS-SCID mice were rested for 4 wks prior to MPTP
intoxication.
3H-Thymidine in vitro Proliferation Assays
Samples of pooled immunized donor cells used for adoptive
transfer were tested for their proliferative capacity by
3H-
thymidine incorporation after stimulation with either immunizing
or irrelevant antigen. Donor SPC were plated at a density of
Immunity and Neurodegeneration
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6 cells/ml complete RPMI tissue culture media [RPMI 1640
supplemented with 10% fetal bovine serum (FBS), 2 mM L-
glutamine, 10 mM HEPES, 1 mM sodium pyruvate, 16 nones-
sential aa, 55 mM 2-mercaptoethanol, 100 U/ml penicillin, and
100 mg/ml streptomycin (Mediatech Inc., Herndon, VA)]. SPC
from PBS, 4YSyn, and N-4YSyn immunized mice were stimulated
with 0, 1, 10, 50 mg/ml of immunizing antigen, 4YSyn or N-
4YSyn, and cultured at 37uC for 5 days. Cells were pulsed with
1 mCi
3H-thymidine/well for the final 18 hrs of culture, harvested
onto glass fiber plates, and counted by b-scintillation spectrometry
(TopCount, Packard-PerkinElmer Instruments, Wellesley, MA).
Western Blot Analysis
Ventral midbrain (VMB) and lymphoid organ protein extracts
(80 mg/lane) were separated by 16% SDS-PAGE (Invitrogen) and
transferred for 45 min onto 0.2 mm PVDF membranes (Millipore,
Bedford, MA). Membranes were probed with rabbit antibodies to
NT (1:2000; Chemicon) or monoclonal rat antibodies to myelin
basic protein (MBP, 1:1000, Chemicon) or guinea pig antibodies
to a-Syn (1:1000; Ab-1, Oncogene/EMD Biosciences). Appropri-
ate HRP-conjugated secondary antibodies (Santa Cruz Biotech-
nology, Santa Cruz, CA) were used to visualize blots using
SuperSignal West Pico Chemiluminescent substrate and CCL-
XPosure film (Pierce Biotechnology, Inc., Rockford, IL). Immu-
noblots were stripped and reprobed with antibodies to a-actin
(1:5000; Chemicon,) as an internal control.
Identification of a-Syn in MPTP-CLN
Anti-N-a/b-syn (clone nSyn12, mouse ascites, Upstate) that
specifically recognizes N-a-Syn (14.5 kD) and N-b-Syn (17 kD)
but not non-nitrated a/b-Syn was used for immunoprecipitation
(IP). VMB and CLN from PBS or MPTP treated mice were
dissected out, homogenized in ice-cold RIPA buffer, pH 7.4 and
centrifuged at 10,0006g for 10 min at 4uC to remove cellular
debris. Protein A/G PLUS-Agarose beads (Santa Cruz Biotech-
nology) were added to 2 mg total cellular protein, incubated for
1h ra t4 uC. Beads were centrifuged at 1,0006g for 5 min at 4uC.
The supernatant was incubated with 40 ml anti-N-a-Syn overnight
at 4uC on a rotating device, and then with Protein A/G PLUS-
Agarose beads for 1 hr on a rotating device at 4uC. Immunopre-
cipitates were collected after centrifugation at 1,0006g for 5 min
at 4uC, washed once with RIPA buffer and twice with PBS,
resuspended in 40 mlo f1 6electrophoresis sample buffer.
N-a-Syn IP samples were fractionated by large format 16%
Tricine SDS-PAGE (Jule Inc., Milford, CT; BIORAD Laborato-
ries, Inc, Los Angeles, CA) at constant voltage for 8–10 hrs. The
gel was stained with highly sensitive SYPRO Ruby stain
(Invitrogen) and scanned at excitation (400 nm) and emission
(630 nm) wavelengths using Typhoon scanner (Amersham Biosci-
ences, Piscataway, NJ) to visualize the protein bands. Small gel
fragments (3–4 mm) corresponding to molecular weight (12–
18 kD) were excised from each lane of the same gel stained with
Coomassie. In brief, gel pieces were destained for 1 hr at room
temperature using 100 ml of 50% ACN/50 mM NH4CO3. Gel
pieces were dried and incubated with trypsin in 10 mM NH4CO3
(Promega, Madison, WI) overnight at 37uC. Peptides were
extracted by washing gel pieces twice with 0.1% TFA and 60%
ACN. Dried samples were resuspended in 12 ml of 0.1% formic
acid in water for automated injection. All samples were purified
using ZipTip (Millipore) prior to MS analysis. In-gel trypsin
digested proteins were fractionated on microcapillary RP-C18
(Ciborowski et al., 2004). The resulting peptides were sequenced
using Electrospray Ionization (ESI)-LC MS/MS (Proteome X
System with LCQDecaPlus mass spectrometer, thermoElectron,
Inc., San Jose, CA) with a nanospray configuration. The spectra
obtained from LC-MS/MS analysis were searched against the
NCBI.fasta rodent protein database using SEQUEST search
engine (BioWorks 3.2 SR software from ThermoElectron, Inc, San
Jose, CA.). Criteria for high confidence protein identification were
used as previously published [38,39,40,41,42,43].
Flow Cytometry
Single cell suspensions were prepared from deep CLN from
C57BL/6 mice 20–24 hrs post PBS or MPTP (18 mg/kg)
intoxication. Cell suspensions were analyzed for cell surface
expression of CD11c, CD11b, and MHC class II (I-A
b). Also, prior
to adoptive transfers, cell populations from immunized donors
were stained for T cells using PE conjugated anti-mouse CD3e
(BD Pharmingen) and B cells with FITC conjugated anti-mouse
CD19 (BD Pharmingen). Analysis was performed with a
FACSCalibur flow cytometer interfaced with CellQuest software
(BD-Biosciences, Immunocytometry Systems, San Jose, CA).
Determination of N-4YSyn-mediated Toxicity In
Vitro
For proliferation analyses, purified T cells from naı ¨ve B6 mice
were plated with SPC irradiated at 3000 rad (1:3) at 2610
6 cells/
ml in complete RPMI tissue culture media and activated with anti-
CD3 (0.5 mg/ml, 145-2C11; BD Pharmingen) in U-bottom 96-
well tissue culture plates. Graded concentrations of 4YSyn or N-
4YSyn were added to quadruplicate wells. After activation for
3 days,
3H-thymidine incorporation was performed as described
previously.
To assess a-Syn-mediated cytotoxicity, purified T cells were
stimulated with anti-CD3 and cultured at a density of 1610
6 cells/
ml for 24 hrs in media alone or in the presence of 4YSyn or N-
4YSyn at concentrations of 1, 3, 10, or 30 mg/ml. Cells were
stained with PI, washed and the percentages of PI
+ dead cells and
MFI were analyzed by flow cytometry.
Macrophage and MES 23.5 Cultures
BMM were prepared from C57BL/6 adult male (6–12 weeks old)
mice. The animals were sacrificed by CO2 asphyxiation. Single
cell suspensions of bone marrow cells were obtained from femur
bone marrow cavities after flushing with HBSS, and red blood
cells lysed with ACK buffer. The bone marrow cells were cultured
in complete DMEM medium (Dulbecco’s Modified Eagles Media
supplemented with 10% FBS, 2 mM L-glutamine, and 1%
penicillin/streptomycin) containing 2 mg/ml macrophage colony
stimulating factor (MCSF), a generous gift from Wyeth Pharma-
ceuticals (Cambridge, MA) in a 5% CO2/37uC incubator. Non-
adherent cells were removed from flasks at 1, 4, and 7 days by
successive DMEM washes. Adherent BMM were harvested and
replated for experiments following 7–14 days of culture. Cells
from the MES 23.5 dopaminergic cell line kindly provided by Dr.
Stanley Appel, were cultured in 75-cm
2 flasks in DMEM/F12 with
15 mM HEPES (Invitrogen) containing N2 supplement (Invitro-
gen), 100 U/ml of penicillin, 100 mg/ml streptomycin, and 5%
FBS. Cells were grown to 80% confluence then co-cultured with
BMM in serum free MEM/F12 at a density of 1610
5 cells (1:1) on
sterile glass coverslips.
N-a-Syn SPC-Induced Microglia Cytotoxicity
SPC isolated from N-4YSyn (10 mg) immunized B6 mice were
cultured in RPMI media and activated in vitro for 4 days with N-
Immunity and Neurodegeneration
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23.5 and macrophage co-cultures were stimulated with aggregated
N-a-Syn (1.45 mg/ml) alone and in combination with either
activated SPC or supernatants obtained from activated SPC for
24 hrs. Unstimulated cultures served as controls. Assays for viable
and dead cells were performed with Live/Dead Viability/
Cytotoxicity kit (Invitrogen) according to the manufacturer’s
protocol and viewed under a fluorescence microscope (Nikon
Eclipse E800, Buffalo Grove, IL). Images were captured at 1006
magnification and quantification of live (green) and dead (red)
counts was performed from 4–8 different fields.
Cytokine array
Triplicate co-cultures of antigen presenting cells (APC) and T cells
from PBS-, 4YSyn- and N-4YSyn-immunized mice were stimu-
lated with 4YSyn or N-4YSyn. After 24 hours of culture, 50 ml
samples were collected, centrifuged, and supernatants frozen at
280uC until utilized. Frozen supernatants were thawed only once
and analyzed using the BD Cytometric Bead Array Mouse Th1/
Th2 Kit (BD Biosciences, San Jose, CA) according to the
manufacturer’s instructions.
Statistical Analysis
All values are expressed as mean6SEM. Differences among
normally distributed means were evaluated by Student’s t test for
two group comparisons or one-way ANOVA followed by
Bonferroni post-hoc tests for pairwise comparisons amongst
multiple data sets (Statistica v7, Statsoft, Tulsa, OK, and SPSS
v13, SPSS, Inc., Chicago, IL) and were considered significant at p
# 0.05 unless otherwise indicated. Kolmogorov-Smirnov (K-S)
analysis was performed for flow cytometric data analysis.
RESULTS
CNS Antigens Drain to CLN Following MPTP
Intoxication
To determine if CNS antigens drain to CLN during established
neurodegeneration of the nigrostriatal pathway, their presence in
ventral midbrain (VMB), cervical, axillary, inguinal, mesenteric
lymph nodes and spleens were determined 24 hrs after MPTP-
intoxication in C57BL6 mice. The presence of unmodified a-Syn
was demonstrated in VMB and CLN (Figure 1A) as well as other
lymph nodes and in the spleen from phosphate-buffered (PBS)- or
MPTP-treated mice in anti-a-Syn-probed immunoblots (data not
shown). These findings also confirmed the expression of
unmodified a-Syn amongst cells of hematopoietic lineage [44].
N-a-Syn IP showed that N-a-Syn was present in the CLN of
MPTP-treated, but not PBS-treated mice as similar molecular
weight bands were observed from gels probed with SYPRO Red
and Western blots performed with a-Syn antibodies (Figure 1B).
To validate the presence of NT-modified a-Syn after MPTP
treatment, N-a-Syn immunoprecipitates were obtained after in-gel
tryptic digestion of 12–18 kD fragments acquired from the VMB
and CLN and sequenced by LC-MS/MS. This regions was chosen
as it represents the molecular mass ranges of oxidized a-Syn
[6,14,45,46,47]. Sequence analysis demonstrated a-Syn peptides
(yellow highlighted sequences, Figure 1C) in the VMB from both
PBS- and MPTP-treated mice but exclusively in the CLN of
MPTP-intoxicated mice (Table 1). a-Syn peptides were identified
at .99.999% confidence (Table 1). Western blot analysis of
lymphoid tissue homogenates using rabbit NT antibodies detected
a single band with a molecular mass of ,16–18 kD–which is
comparable to that of a-Syn–in CLN from MPTP-intoxicated
animals, but not in other lymph nodes or spleen (Figure 1D, blots
of mesenteric lymph nodes and spleen are not shown). These
results were confirmatory for the presence of N-a-Syn in the
draining CLN. Another CNS antigen, MBP was also detected only
in the CLN of MPTP intoxicated animals (Figure 1D). NT-
modified proteins and MBP were absent in lymph nodes and
spleens of control (PBS-injected) mice. These data suggest that
brain proteins released as a consequence of nigrostriatal injury,
drain to the deep CLN, placing them in organs associated with
efficient presentation of antigen. To demonstrate the functional
significance of these observations, single cell suspensions were
prepared from CLN isolated from MPTP animals and controls,
and analyzed by flow cytometry for MHC class II expression on
CD11b
+ APC (Figure 1E). Increased frequencies of CD11b
+/
MHC class II
+ in MPTP-treated mice compared to PBS controls
was taken as evidence of leukocyte activation in the deep CLN
following MPTP-induced nigrostriatal injury. Supporting the
induction of a a-Syn specific immune response, sera from WT
B6 mice 21 days after chronic MPTP intoxication were analyzed
for anti-a-Syn IgG and compared to animals that received PBS.
Serum levels of a-Syn antibodies in mice exposed to MPTP were
significantly increased (Figure 1F). Together, these results
demonstrate that NT-modified a-Syn draining into the deep
CLN is capable of eliciting a peripheral immune response.
Adaptive Immunity Participates in MPTP-Nigral
Degeneration
The presence of NT modifications of a-Syn in draining lymphatic
tissue following MPTP-induced nigrostriatal injury, along with
evidence of lymphoid-associated APC activation provided support
for antigen presentation to T cells and subsequent immune
responsiveness. To substantiate this idea, we explored whether an
endogenous adaptive immune system was required for MPTP-
induced nigrostriatal degeneration. B6 WT mice, B6 SCID mice,
and B6 SCID mice reconstituted with 10
8 B6 WT splenocytes
(SPC) (RCS-SCID) were treated with PBS or a chronic MPTP
regimen. Mice were sacrificed at 21 days after the last MPTP
injection, and VMB sections immunostained for tyrosine hydrox-
ylase (TH), the rate-limiting enzyme in dopamine synthesis
(Figure 2A, left panels). The numbers of TH
+ neurons in the SN
showed a 33% reduction in WT B6 animals that received MPTP
compared to those that received PBS (Figure 2B). No significant
difference in the numbers of TH
+ neurons was observed in MPTP-
treated SCID mice compared to SCID mice that received PBS
(Figure 2B). In contrast, immune reconstituted SCID mice (RCS-
SCID) treated with MPTP showed significantly fewer TH
+
neurons compared to the SCID MPTP group (Figure 2A and
2B). To validate the reconstitution of RCS-SCID mice, spleens
were immunostained for CD3
+ T cell distribution (Figure 2A, right
panels). T cell repopulation was confirmed by the presence of
CD3
+ T cells in the periarteriolar lymphoid sheath of RCS-SCID
mouse spleens (Figure 2A),
VMB and cerebellum control sections of WT, SCID, and RCS-
SCID mice treated with MPTP were immunostained for T cells
using antibodies against CD3, CD4, and CD8. CD3 immuno-
staining of MPTP-treated B6 mice demonstrated CD3
+ cells in the
VMB beginning at day 0, present at day 4 after MPTP
intoxication (Figure 2C) that persisted to day 14. Both CD4
+
and CD8
+ subpopulations were also present in VMB of only
MPTP-treated animals at 4 and 14 days (Figure 2C). No T cell
accumulation was observed in PBS or MPTP-treated SCID mice
at any time point (data not shown), whereas CD3
+ T cell
accumulations in VMB of RCS-SCID mice after MPTP-treatment
Immunity and Neurodegeneration
PLoS ONE | www.plosone.org 5 January 2008 | Issue 1 | e1376were identified. Cerebellar tissue of MPTP animals had #1 CD3
+
T cell per high power field examined present suggesting specific
cell entry into affected regions. Taken together, these data support
the occurrence of an adaptive immune response triggered by
modified CNS antigens that modulates the vulnerability of the
dopaminergic neurons to MPTP through the migration of T cells
into the CNS.
Prediction of Mouse N-a-Syn Specific T Cell Epitopes
To test the probability of N-a-Syn induced adaptive immune
responses, we compared the numbers of predicted a-Syn specific T
cell epitopes with the propensity to bind class I MHC grooves [48]
for the murine MHC haplotypes, H-2
k and H-2
b (see Table 2).
However, since the last 40 aa of the mouse a-Syn contains 4 Tyr
residues available for nitration, our analysis focused on this C-
terminal a-Syn fragment. Table 2 shows that H-2K
k epitopes have
a superior ability to bind with high and intermediate affinity a-
Syn-derived 8-11-meric peptide fragments derived from the whole
a-Syn molecule or from its C-terminal 38-meric fragment. These
data demonstrate significant T cell induction potential. In fact, a-
Syn has 100 potential T cell epitopes, 73 of which contain Tyr that
were predicted to bind H-2K
k molecules, while only 8 and 15
potential epitopes may bind H-2D
b and H-2K
b molecules,
respectively. This was also for nitrated epitopes containing Tyr
residue including those with a Tyr residue within the central
region of the epitope that presents prominently to the T cell
Figure 1. Drainage of N-a-Syn and MBP to CLN with macrophage activation and production of a-Syn serum antibodies after MPTP intoxication.
(A) Western blot of tissue homogenates from VMB and CLN of mice 20 hrs following treatment with PBS or MPTP, were probed with antibodies to a-
Syn. (B) N-a/b Syn IP with (clone nSyn12 antibodies) against CLN homogenates from PBS or MPTP-treated mice. Immunoprecipitates were
fractionated on a 16% polyacrylamide gel and the gel stained with SYPRO Red or blotted. The Western blot was probed with anti-a-Syn. (C) Proteins
recovered from in-gel digestion of 12–18 kD fragments from anti-N-a/b Syn of CLN immunoprecipitates were were identified by LC-MS/MS. The
sequence coverage by peptides identified by LC-MS/MS from the CLN of MPTP-treated mice is highlighted in yellow within the primary aa sequence
of full-length mouse a-Syn. (D) Western blots of lymph node homogenates (Cervical, Axillary, and Inquinal) from mice treated with PBS or MPTP. Blots
were probed with antibodies to nitrotyrosine (NT) or anti-myelin basic protein (MBP). (E) Flow cytometric analysis of CD11b and I-A
b expression in
cells from CLN, show an increased number of CD11b
+I-A
+ cells 24 hrs after MPTP treatment compared to PBS administered animals (n=3 mice/
group). (F) Antibodies against a-Syn and N-a-Syn in sera of B6 WT mice on day 21 following MPTP intoxication (n=8) or PBS control treatment (n=5)
as determined by anti-a-Syn specific ELISA. Sera from MPTP treated group contained significantly higher IgG antibodies directed against 4YSyn
(p=0.021) and N-4YSyn (p=0.016) compared to PBS treated control sera. Comparisons of mean IgG concentrations 6 SEM was by Student’s t test.
doi:10.1371/journal.pone.0001376.g001
Immunity and Neurodegeneration
PLoS ONE | www.plosone.org 6 January 2008 | Issue 1 | e1376receptor. These epitopes do not contain anchor aa that mediate
binding to the MHC groove. Dramatic difference in the number of
Tyr-containing T cell epitopes from C-terminal segment of a-Syn
predicted to bind H-2K
k but not any of H-2
b molecules (Table 2,
data in brackets) suggests a potential preference for H-2K
k versus
H-2
b mice to induce T cell responses to nitrated C-terminal
fragments of a-Syn. These fragments, if facing T cell receptors,
have greater chances of inducing MHC class I-restricted CD8
+ T
cells due to lack of negative selection against N-a-Syn epitopes in
the embryonic thymus. Further epitope prediction analysis
revealed a number of 15-meric epitopes, including Tyr-containing
peptides from C-terminal, that can bind with increased affinity
class II MHC groove, thus increasing the propensity of inducing
MHC class II-restricted CD4
+ T cells specific for Tyr-containing
a-Syn C-terminal fragments. Therefore, mice expressing MHC
class I and II molecules of H-2
k haplotypes are capable of
generating immune responses to NT-modified a-Syn. Interesting-
ly, that a-Syn C-terminal fragment contains several Tyr-contain-
ing peptides with predicted significant binding affinity for IA
k and
IA
b MHC molecules (18 and 14 epitopes, respectively) suggests a
significant potential for CD4
+ T cells of mice expressing IA
k or IA
b
to respond to nitrated epitopes from a-Syn C-terminal.
Purification and Nitration of Recombinant a-Syn
Based on our findings, we hypothesized that in PD, NT
modifications of a-Syn could be a key step converting the
endogenous protein to an immunogen. Here, we used the C-
terminal 40 aa a-Syn fragment (4YSyn) as it contains all four
tyrosine residues that are nitrated, thus limiting the possible
specificities of epitopes capable of generating an immune response.
For this, the mouse cDNA encoding the final 40 aa was cloned
into the bacterial pET-28a His-tag expression vector and
recombinant protein expressed in BL21 E. coli following
isopropyl-b-D-thiogalactopyranoside (IPTG) induction. Expres-
sion of the recombinant protein exhibited no apparent toxicity to
the bacterial expression system. Affinity-purified 4YSyn peptide
from E. coli lysates was detected as a prominent single band using
silver staining on 12% polyacrylamide gel (Figure 3B) and by
Western blot using a polyclonal antibody raised against aa 120–
140 of a-Syn (Figure 3C). Reverse-phase high performance liquid
Table 1. Probabilities (p values) of protein sequence matches within 12–18 kD bands from anti-N-a/b-synuclein
immunoprecipitation and LC MS-MS analyses of VMB and CLN from PBS- or MPTP-treated mice.
..................................................................................................................................................
Protein match P value for protein matches from:
VMB CLN
PBS MPTP PBS MPTP
a-synuclein 5.9610
27 7.7610
26 1.0610
26
b-synuclein 4.3610
27 3.8610
29
myelin basic protein 3.4610
25
MHC class I antigen 4.0610
23
immunoglobulin heavy chain variable region 5.8610
25
chemokine-like factor super family five variant 4 3.8610
24
ribosomal protein S14 5.6610
26
Tesp4 protein 1.8610
25
A chain A, complex of the second kunitz domain of tissue factor pathway inhibit 2.0610
24 8.7610
25
structural constituent of ribosome 6.3610
25
parotid secretory protein 2.6610
24
ribosomal protein S14 4.9610
24
Similar to NADH dehydrogenase (ubiquinone) 1 beta subcomple 5.9610
24
mediator of RNA polymerase II transcription, subunit 8 homolog isoform 9.9610
24
cAMP-dependent protein kinase, alpha-catalytic subunit (PKA C-alpha) 1.3610
23
step II splicing factor SLU7 2.4610
23
parotid secretory protein 3.5610
23
Similar to protease, serine, 3 1.2610
25
hypothetical protein LOC320696 4.5610
23
Unknown (protein for MGC:116262) 2.9610
26
unnamed protein product (16288 kD) 1.6610
24
unnamed protein product (25311 kD) 1.1610
25
unnamed protein product (27163 kD) 2.4610
24
unnamed protein product (58621 kD) 1.2610
25 8.2610
25
unnamed protein product (65626 kD) 2.7610
26 1.4610
25 2.5610
25
pancreatic trypsin 1 3.7610
25 2.7610
26 1.5610
26 1.3610
24
trypsin 10 2.9610
23 1.8610
24 5.1610
25 8.6610
25
trypsinogen 7 2.2610
25 2.6610
26
doi:10.1371/journal.pone.0001376.t001
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PLoS ONE | www.plosone.org 7 January 2008 | Issue 1 | e1376chromatography (RP-HPLC) analysis of isolated 4YSyn products
demonstrated purities equal to or in excess of 97%. NT
modifications of 4YSyn peptide (N-4YSyn) after peroxynitrite
nitration was confirmed by Western blot using mouse monoclonal
anti-NT antibody (Figure 3C).
Homogeneity of purified 4YSyn and its modified forms
(aggregated and nitrated) was assessed based on: 1D SDS-PAGE
(Figure 3B), Western blot (Figure 3C), and matrix-assisted laser
desorption ionization-time of flight (MALDI-TOF) mass spec-
trometry (Figure 3D). The predominant peak for 4YSyn by
MALDI-TOF analysis was 6592 m/z, which corresponded to the
6718 expected mass of purified recombinant a-Syn within ,2%
mass accuracy (Figure 3D and Table 3). To provide proof that the
mass discrepancy originated from recombination errors within the
His-tag region obtained during protein purification, but not within
the biologically active portion of the molecule, we digested the
recombinant 4YSyn protein with trypsin and measured masses of
resulting fragments using MALDI-TOF. The observed masses of
the generated fragments were Arg-cleaved 4YSyn and Lys-cleaved
4YSyn. These corresponded to the expected masses with 0.07% of
mass accuracy. Next, we compared the mass of native 4YSyn to N-
4YSyn. The oxidized peptide or its trypsin cleaved fragments
revealed a 184 D mass increase that is analogous to the expected
mass of 4 nitro groups corresponding to 4 NT- residues (Figure 3A
and 3D). Based on these observations, we concluded that reaction
of 4YSyn with peroxynitrite, under the conditions used in this
study, efficiently nitrated all four available Tyr residues in 4YSyn.
N-4YSyn Induces Specific Immune Responses in
B10.BR Mice
To test our predictions of immune responses to N-a-Syn, B10.BR
(H-2
k) mice were immunized with N-4YSyn, 4YSyn, or PBS each
emulsified in complete Freund’s adjuvant (CFA) (Figure 4A).
Fourteen days following the initial immunization, mice were
boosted with their respective immunogens emulsified in incom-
plete Freund’s adjuvant (IFA). Five days later, mice were sacrificed
and SPC were tested for antigen-specific T cell proliferative
responses to N-4YSyn or 4YSyn. Stimulation with 4YSyn yielded
no significant immune responses regardless of whether mice were
immunized with adjuvant containing PBS, 4YSyn or N-4YSyn
(Figure 4B). In contrast, significant proliferative responses were
afforded from SPC of mice immunized with N-4YSyn and
challenged in vitro with N-4YSyn, but not 4YSyn. Moreover, N-
4YSyn stimulated SPC from mice immunized with adjuvant
containing 4YSyn or PBS failed to induce significant proliferative
responses. These data indicate that immunization with N-4YSyn,
but not 4YSyn is capable of inducing antigen specific immune
responses to NT-modified CNS antigens.
Adoptive Transfer of N-4YSyn SPC and T Cells
Exacerbates MPTP-induced Microglial Activation
and Dopaminergic Neuronal Death
In light of the fact that modified a-Syn is capable of evading
tolerance and inducing reactive T cells, we next tested whether
Figure 2. Nigral degeneration following MPTP-intoxication in B6 SCID mice before and after lymphoid cell reconstitution. (A) Photomicrographs
of TH-immunostained SN (left panels) and CD3-immunostained spleen sections (right panels) from B6 (WT), SCID, and reconstituted SCID (RCS-SCID)
mice treated with PBS or MPTP and obtained on day 21 post-MPTP intoxication. Immunostaining for expression of CD3 in spleens show normal
distributions of CD3
+ T cells in B6 WT and RCS-SCID mice treated with PBS or MPTP. Note the absence of CD3
+ T cells in spleens from SCID MPTP mice.
(B) Quantification of TH+ neurons in the SN of B6 WT, SCID, or reconstituted (RCS) SCID mice treated with PBS or MPTP. Values represent mean
number of TH+ neurons 6 SEM for 5-9 mice per group.
abcdefgPair-wise comparisons by Bonferroni post-hoc test:
acdp,0.0001,
befp,0.001,
gp,0.05.
(C) Coronal VMB sections of MPTP intoxicated B6 mice reacted with antibodies against CD3, CD4 and CD8 show positive immunostaining of cells with
small, round lymphocytic morphology (magnification=400X).
doi:10.1371/journal.pone.0001376.g002
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PLoS ONE | www.plosone.org 8 January 2008 | Issue 1 | e1376modified a-Syn-activated T cells could exacerbate MPTP-induced
dopaminergic neurodegeneration. The experimental scheme for
adoptive transfer of SPC or purified T cells from immunized
animals is outlined in Figure 4A. For these studies, B10.BR (H-2
k)
donor mice were immunized and boosted with N-4YSyn or
4YSyn, and SPC were adoptively transferred to MPTP-treated
syngeneic recipients. To delineate effects due specifically to T cells,
CD3
+ T cells were enriched by negative selection and transferred
to an additional group of MPTP-treated animals. Flow cytometric
analysis showed that the enriched population from N-4YSyn mice
was 94% CD3
+ T cells (Figure 5A). Adoptive transfer of purified T
cells from N-4YSyn immunized donors to MPTP intoxicated mice
revealed CD3
+ T cell infiltrates in the SNpc on day 2 after MPTP
treatment (Figure 5B).
MPTP treated mice showed fluorescent neurons within the SN
using the degenerating cell marker Fluoro-Jade C by day 2, but
not by day 7 (Figure 6, left and middle panels) confirming previous
kinetic data regarding MPTP-induced nigral neuronal death
obtained by silver staining techniques [49]. MPTP treated mice
that received immune cells from N-4YSyn immune mice showed
more Fluoro-Jade C stained neurons within the SN by day 2 than
MPTP-intoxication alone, and, in contrast to the latter, Fluoro-
Jade C stained neurons within the SN by day 7 as well. In the PBS
control group, no Fluoro-Jade C stained neurons were observed at
any time point. Following MPTP administration, microgliosis is
striking and immediate. Our initial time course studies are in line
with these findings and show that the microgliosis and dopami-
nergic neurodegeneration in B10.BR mice are virtually resolved
respectively by days 4 and 7 post-MPTP injection (Figure 6, right
and middle panels, respectively). However, adoptive transfer of
SPC from B10.BR mice, regardless of immunization protocol, was
associated with a persistent microglial response, as evidenced by
quantitative morphology with Mac-1 immunostaining (Figure 6,
right panel). Counts of Mac-1
+ microglia were greatest (p,0.0001)
in MPTP mice treated with SPC from N-4YSyn immunized mice
[84.167.0/mm
2 (mean6SEM)] compared to those from mice
treated with MPTP and SPC from 4YSyn immunized mice
(26.963.5/mm
2), MPTP alone (27.763.2/mm
2), or PBS
(0.760.3/mm
2). These data suggest that the adaptive immune
components of H-2
k mice following MPTP administration contrib-
ute to the neuroinflammatory phenotype seen in these animals.
Based onthesefindings,we nextinvestigated whether theimmune
response mediated by N-a-Syn affects degeneration of dopaminergic
cell bodies in the SNpc. To test this, MPTP-intoxicated B10.BR
mice received 5610
7 donor SPC from mice immunized with PBS,
4YSyn, or N-4YSyn, or 2.5610
7 enriched T cells from 4YSyn-
immunized donors. PBS- and MPTP-treated mice that did not
receive cells served as controls for no neuronal loss and loss
attributable to MPTP treatment alone, respectively. PBS-treated
mice that received N-4YSyn immunized donor SPC served as
additional controls. VMB sections were obtained from mice at 2, 7,
and 28 days following MPTP treatment and immunostained for TH
(Figure 7A). Stereological analysis showed that MPTP induced a
45% reduction of SN TH
+ neurons compared to PBS controls
(Figure 7B). Similar results were observed in MPTP-injected mice
that received SPC from PBS or 4YSyn immune donors (MPTP/
PBS/SPC and MPTP/4YSyn/SPC, respectively). In contrast,
recipients that received immune N-4YSyn SPC (MPTP/N-
4YSyn/SPC) or N-4YSyn T cells (MPTP/N-4YSyn/T Cells)
exhibited significantly greater reductions of SNpc TH
+ neurons
(64 and 63%, respectively) compared to all other MPTP-treated
animals (Figure 7B). PBS-treated mice that received immune SPC
from N-4YSyn immunized donors showed no change in TH
+
neuron numbers, demonstrating the necessity for an initiating
neuronal insult. Significant effects from any treatment were not
observed among the numbers of non-dopaminergic neurons
(Nissl+TH-). Correlation analysis of total Nissl+ neurons compared
to TH+ and TH- neurons demonstrated that the number of total
neurons strongly correlated with numbers of TH+ neurons
(r=0.981, p,0.0001) compared to numbers of TH- neurons
(r=0.522, p=0.004). This confirmed that differences in TH+
neuroncounts aredue to differencesinnumbersof structurallyintact
neurons and eliminates the possibility that differences resulted from
the down-regulation of TH itself. Thus, these data demonstrate that
adaptive immune responses against the nitrated form of a-Syn
exacerbated MPTP-induced nigrostriatal degeneration.
Based on MHC binding affinity algorithms, mice expressing H-2
b
werepredicted torespond poorly to a-Syn epitopes;yet 21 days after
chronic MPTP-intoxication, B6 mice that express the H-2
b
haplotype yielded significant antibody responses to N-a-Syn. This
suggested that mice expressing H-2
b have the potential to develop
immune responses to N-a-Syn that may affect disease progression.
To assess that possibility, we immunized and boosted B6 (H-2
b)m i c e
with 4YSyn or N-4YSyn either in PBS or emulsified in adjuvant
(Figure 8A). Five days after the final boost SPC were harvested,
assessed forantigenspecificlymphocyteproliferation, andadoptively
transferred to MPTP-intoxicated recipients. Stimulation of SPC
from PBS-treated controls indicated that neither 4YSyn nor N-
4YSyn induced significant proliferation above medium background
levels (Figure 8B). In contrast, stimulation of SPC from N-4YSyn/
PBS immunized mice with N-4YSyn induced a significant
lymphocyte proliferative response indicating that immunization
withN-4YSyn/PBSintheabsenceofadjuvantiscapableofinducing
an antigen specific adaptive immunity.
TH stained sections of VMB from MPTP-intoxicated mice that
received SPC from donors immunized with N-4YSyn either in
PBS excipient or adjuvant showed significant dopaminergic
Table 2. Numbers of putative a-Syn epitopes for presentation
to T cell receptors predicted from the binding potential of
MHC class I and II molecules for the aa sequence of a-Syn.
......................................................................
Predicted binding
of epitopes Number of predicted epitopes for:
aMHC class I
bMHC class II
K
k D
b K
b IA
k IE
k IA
b
All 143 (100) 72 (1) 73 (13) 116 (32) 59 (8) 129 (32)
High 29 (26) 1 (0) 1 (1) 19 (12) 0 (0) 2 (2)
Intermediate 71 (58) 7 (0) 14 (6) 55 (13) 6 (1) 70 (16)
Low 43 (16) 64 (1) 58 (6) 42 (7) 53 (8) 57(14)
Containing Tyr 101 (77) 50 (1) 48 (8) 34 (23) 8 (5) 33 (24)
High 24 (21) 1 (0) 1 (1) 9(10) 0 (0) 2 (2)
Intermediate 49 (43) 7(0) 12 (4) 19 (8) 0 (0) 16 (12)
Low 28 (13) 42 (1) 35 (3) 6 (5) 8 (5) 15 (10)
Number of predicted T-cell epitopes from the 38-mer C-terminal fragment of a-
Syn are in brackets.
aFor class I MHC binders three following grades for scoring
included: low immunogenic epitopes, scores ,23; mild immunogenic
epitopes, scores .23 but ,22; high immunogenic, scores .22; all
computations were done using the Immune Epitope Database and Analysis
Resource (IEDB) (http://immuneepitope.org) and integrative epitope prediction
tool [proteasomes cleavage, Transporter associated with Antigen Processing
(TAP) binding, processing and MHC binding].
bFor class II MHC binders, scoring
grades were based on predicted IC50 values and were: low (1000 nM–5000 nM),
intermediate (200–1000 nM) and high (,200 nM) for groove binding prediction
by MHCPred. This prediction algorithm considers peptides with predicted IC50
.5000 nM as non-binders [86,87].
doi:10.1371/journal.pone.0001376.t002
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PLoS ONE | www.plosone.org 9 January 2008 | Issue 1 | e1376neuronal losses compared to MPTP-treated mice or those that
received SPC from 4YSyn immunized mice (Figure 9A), suggest-
ing 4YSyn immunization increased the MPTP-induced lesion.
Next, we assessed the sections by stereological analysis to obtain
estimates of dopaminergic neuronal survival and loss after
treatment compared to PBS-treated mice. MPTP-intoxication of
B6 mice induced 43% loss of TH+ nigral neurons compared to
PBS-treated controls (Figure 9B). Numbers of dopaminergic
neurons from MPTP mice treated with SPC from 4YSyn
immunized mice were not significantly different compared to
MPTP-treated mice and showed a similar 42% loss of neurons.
However, adoptive transfer of SPC from N-4YSyn/Adjuvant
immune donors significantly increased MPTP-induced dopami-
nergic neuron loss to 58%. Interestingly, SPC from mice
immunized with N-4YSyn without adjuvant induced a 69% loss
of nigral TH+ neurons after MPTP intoxication, which was
significantly greater than losses due to SPC from 4YSyn- or N-
4YSyn/Adjuvant immunized donors. Neither MPTP treatment
nor adoptive transfer of immune SPC significantly affected
numbers of non-dopaminergic neurons. Thus, taken together
these data demonstrate that N-a-Syn, but not unmodified a-Syn,
has the capacity to induce specific immune responses by which
exacerbates neuronal loss in the context of dopaminergic
neurodegeneration. Moreover, these results in H-2
b mice,
Figure 3. Characterization of purified and nitrated recombinant 4YSyn. (A) Primary aa sequence of His-tagged 4YSyn peptide. The His-Tag
sequence is highlighted in yellow. The sequence of 4YSyn (Syn100–140) is shown underlined with 4 Tyr residues (magenta) as potent sites for nitration.
Trypsin cleavage sites at Arg (arrowhead) and Lys (arrow) are shown. (B) Purified 4YSyn (lane 1) and N-4YSyn following nitration with peroxynitrite
(lane 2) fractionated on a 10–20% polyacrylamide gel and visualized using silver stain. Covalently cross-linked oligomers are indicated by arrowheads.
(C) Western blot confirmation of purified 4YSyn and its associated NT modifications following peroxynitrite treatment. (D) MALDI-TOF spectra of
purified 4YSyn (top panel), N-4YSyn (middle panel), and 4YSyn after tryptic digest (lower panel).
doi:10.1371/journal.pone.0001376.g003
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PLoS ONE | www.plosone.org 10 January 2008 | Issue 1 | e1376predicted to provide poor immune response, suggests that epitopes
modified by inflammatory processes may function unlike their
tolerated unmodified self-analogues to induce immune responses
to levels sufficient to alter disease progression.
Nitrated a-Syn Inhibits Proliferation of Anti-CD3
Activated T Cells
We observed that antigen specific proliferative responses were
inhibited by N-4YSyn in a dose dependent manner (r
2=0.96,
p=0.002). Significant inhibition was not seen by 4YSyn (r
2=0.53,
p=0.273). To rule out an antigen specific suppressive effect, purified
T cells obtained from naı ¨ve mice were stimulated with anti-CD3 for
24 hrs in media or in the presence of 4YSyn or N-4YSyn at
concentrations of 1, 3, 10 and 30 mg/ml. N-4YSyn inhibited
proliferation of anti-CD3 stimulated T cells in a dose dependent
fashion (r
r=0.6803, p,0.0001). A significant inhibition of 31 and
47% was observed when stimulated T cells were co-cultured at N-
4YSyn concentrations of 10 and 30 mg/ml (Figure 10). In contrast,
proliferation of anti-CD3 stimulated T cells was not inhibited by
4YSyn (p=0.435) or by increasing 4YSyn concentration
(r
2=0.1554, p=0.0854). Moreover, the inverse effect on anti-CD3
activated T cells with increasing N-4YSyn concentration was greater
(p=0.016) compared to that induced by 4YSyn. Second, to assess
whether this effect was due to a cytotoxic mechanism, anti-CD3
stimulated T cells were stained for the membrane impermeant DNA
dye, propidium iodide (PI) that is excluded from intact, living cells,
and analyzed by flow cytometry. T cells cultured in the presence of
N-4YSyn exhibited a dose-dependent increase in the mean
fluorescent intensity (MFI) of PI (r
2=0.9261, p=0.0008) and in
the percentageofPI
+dead T cells(r
2=0.9743,p=0.0018)(Table4).
In comparison, percentages of PI stained dead T cells cultured with
4YSyn and the PI MFI were not different from the basal level in
absence of either of the peptides and did not change with increasing
4YSyn concentration (r
2=0.5983, p=0.1249, and r
2=0.5016,
p=0.1807, respectively). Taken together, increasing N-4YSyn
concentrations strongly correlated with inhibition of T cell
proliferation, percent PI
+ T cells, and increased MFI for PI
(r.0.945, p,0.0154 for all comparisons combined). In contrast,
no significant correlations were associated with increasing 4YSyn
concentrations. Thus, cytotoxic interference of immune response
induction by N-a-Syn may affect disease progression as these
processes are shared by both effector and regulatory T cells.
N-4YSyn-Stimulated Immune SPC Enhance
Dopaminergic Cell Death
To directly test the neurotoxic capacity of the N-4YSyn immune
response, proliferating T cells or supernatants from N-4YSyn
stimulated SPC of N-4YSyn immunized mice were assessed in
live/dead assays with co-cultures of N-a-Syn activated bone marrow-
derived macrophages (BMM) and MES 23.5 cells. Minimal
cytotoxicity was afforded from co-cultures of unstimulated BMM/
MES 23.5 co-cultures with virtual 100% MES 23.5 cell survival,
whereas activation with aggregated N-a-Synresultedin7%celldeath
after 24 hrs (Figure 11). Activated and proliferating T cells from
5 day cultures of antigen-specific stimulation of N-4YSyn immune
SPC when added to activated BMM/MES 23.5 cultures induced
21% cell death (N-4YSyn+SPC), while supernatants (Sup) from those
SPC cultures resulted in 44% cell death (N-4YSyn+SPC Sup),and no
cytotoxicity to activated BMM cultured in the absence of MES 23.5
cells (Macrophages+SPC Sup). In transwell studies wherein N-
4YSyn-stimulated BMM was separated from MES 23.5 targets,
virtually all cytotoxicity was concentrated among the MES 23.5 cell
population (MES 23.5 Transwell) with no cytotoxicity attributed to
BMM. T cells isolated from N-4YSyn-immunized donors and re-
stimulated in vitro with N-4Ysyn, but not 4YSyn, showed TNF-a
levels (26.061.2 pg/ml) that were increased (p,0.008) compared to
levels from T cells of either PBS or 4YSyn immunized mice which
were below the limits of detection (data not shown).
DISCUSSION
This study provides direct evidence that the adaptive immune
system can exacerbate dopaminergic neuronal loss in animal
models of PD. Nitrated proteins that drain from the CNS into
lymphatics induce macrophage activation and T cell responses.
Moreover, we show that these T cell responses to N-a-Syn elicit
profound neurodegeneration. Cell damage resulting from N-a-Syn
is not limited to brain cells as it affects both T cell function and
numbers, and may, in fact, affect regulatory T cell subsets
(Reynolds, et al. 2007, in press). Our data, taken together, suggests
that an exacerbated immune response induced by N-a-Syn may
play a role in PD pathogenesis.
Under homeostatic conditions a-Syn exists in equilibrium
between soluble and lipid membrane bound forms. Unmodified
soluble a-synuclein retains a native unfolded structure in its soluble
state [6,50] and exhibits an a-helical structure when membrane
bound; the latter being less prone to fibrillation and nitrate
modifications [7,51,52]. However under disease conditions, a-Syn
develops a b-pleated sheet configuration permissive for filament
formation [53]. Nitrate modifications can prevent a-helical
formation, increase b-sheet and oligomer formation, and prolong
the intracellular protein half-life by reducing the capacity for
proteasomal degradation [14,16]. Moreover, N-a-Syn can inhibit
filament formation [14] resulting in increased formation of
oligomeric protofibrils [17,50]. Such oligomeric protofibrils are
cytotoxic through pore-forming activity within the plasma
membrane [54]. Likewise, environmental cues are known to be
linked to PD [55,56] and elicit significant effects on intraneuronal
concentrations, post-translation modifications, conformational
behavior, and aggregation of a-Syn [57]. These observations,
taken together, support an environmental role for sporadic PD.
Peripheral immune abnormalities have been widely described in
PD including the occurrence of autoantibodies against neuronal
structures and high numbers of microglia cells expressing human
leukocyte antigen (HLA)-DR in the nigrostriatal system [58,59].
Disturbed cellular and humoral immune functions in peripheral
blood of patients with PD have been also identified and T cell
infiltration of diseased CNS tissues have been reported [60,61]. An
elevated T cell population expressing c/d T cell receptors and
increased IgG levels in CSF to heat shock proteins have been also
described in PD [62,63]. T helper cell analysis has revealed a
decreased percentage of CD45RA
+ ‘‘naı ¨ve’’ and an increased
percentage of CD45RO
+ ‘‘memory’’ T cell subsets in CD4
+ T cell
Table 3. Theoretical and Observed Masses of 4YSyn, N-4YSyn
and Tryptic Digest Fragments.
......................................................................
Peptide Theoretical Mass (D) Observed Mass (D)
His-Tagged 4YSyn 6718 6592
His-Tagged N-4YSyn 6902 6775
Arg Cleaved 4YSyn 4836 4833
Lys Cleaved 4YSyn (K) 4238 4241
Arg Cleaved N-4YSyn 5020 5073
Lys Cleaved N-4YSyn 4422
doi:10.1371/journal.pone.0001376.t003
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PLoS ONE | www.plosone.org 11 January 2008 | Issue 1 | e1376populations in the peripheral blood of patients with PD [61].
Collectively, these studies suggest that perturbations in the
adaptive immune system may play a role in the progression of
the human disease.
There is mounting evidence that immune abnormalities exist in
PD. Increased HLA expression, CNS T cell infiltration [59], IgG1
deposition in Lewy Bodies, and peripheral immune abnormalities
have been reported. Moreover, the recently demonstrated
Figure 4. Experimental protocol for adoptive transfer and lymphocyte proliferation assessment of donor SPC in B10.BR mice. (A) B10.BR (H-2
K)
mice were immunized with PBS, 50 mg 4YSyn, or 50 mg N-4YSyn emulsified in CFA. Mice were boosted 14 days later with PBS or their respective
antigens in IFA. After 5 days, donor mice were sacrificed and single cell suspensions were prepared from the draining inguinal lymph nodes and
spleen, and T cells were enriched by negative selection. Twelve hours after the final MPTP injection, 5610
7 donor immune SPC or 2.5610
7 T cells were
adoptively transferred to MPTP-treated recipient mice. SPC were evaluated for antigen specificity prior to adoptive transfer by lymphocyte
proliferation assays. SN of recipients were evaluated after 28 days of MPTP treatment for migration of T cells, survival of dopaminergic neurons, and
reactive microglia. (B). SPC were tested for antigen specific proliferation by culturing in the presence of media alone or media containing 3 mg/ml of
immunizing antigens for 5 days and using standard
3H-thymidine incorporation assays.
doi:10.1371/journal.pone.0001376.g004
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PLoS ONE | www.plosone.org 12 January 2008 | Issue 1 | e1376significant increase of the DQB1*06 MHC class II allele in
idiopathic PD may indicate an association between sporadic PD
and the immune system [64]. Le and colleagues reported that
immunization of guinea pigs with homogenized MES 23.5 cell
extracts in CFA resulted in nigrostriatal injury demonstrating the
capability of adaptive immune components to injure dopaminergic
neurons [65]. However, this approach used a cell line derived from
rat embryonic mesencephalon cells that were fused with mouse
neuroblastoma cells as an immunogen in the guinea pig. This
experimental strategy precludes the challenge of breaking
tolerance to self, the primary hurdle in autoimmune pathology,
as mouse or rat proteins would likely be viewed as ‘‘foreign’’ in the
guinea pig. Moreover, this work models PD as a primary
autoimmune disease, for which little supporting evidence exists,
and does not give any indication as to how, or under what
circumstances, such autoimmune reactions may occur. Our data
provides a rationale and a novel mechanism, which includes
immunity to modified self-proteins as a disease modifier, rather
than autoimmunity as a primary pathological mechanism. This
idea nicely supports existing hypotheses where toxic injury
(environmental or endogenous) results in damaged self-proteins
capable of immune activation. Adaptive immune responses may
play a role in amplifying and sustaining innate immune
mechanisms operative in PD. Moreover, this may provide insight
as to why antigenically related sites are also affected in PD such as
the locus coeruleus, raphe nuclei, and nucleus basalis of Meynert.
Innate neuroinflammatory reactions, primarily associated with
activated microglia, significantly contributes to secondary neuro-
nal loss in animal models of PD [66,67]. Mice intoxicated with an
acute regimen of MPTP exhibit a robust inflammatory response,
which precedes neuronal loss and resolves by day 4 post-
intoxication during which most degeneration takes place. The
acute nature of this inflammatory response seen in mice is in
striking contrast to idiopathic PD that slowly progresses over a
period of years. Unlike the mouse data, humans and non-human
primates intoxicated with MPTP have sustained microglial
activation [68,69]. Mechanisms linking innate immune activation
and dopaminergic neuronal cell loss are under active study. One
potential mechanism for sustaining innate neuroinflammatory
reactions includes peripheral activation of the adaptive immune
system against CNS antigens originating in damaged tissue.
Foreign antigen introduced into CNS compartments, including
the anterior chamber of the eye or striatum [70], results in the
education of peripheral T cells in the spleen or CLN, respectively,
and primarily favors tolerance induction [71]. Interestingly,
dendritic cells populate perivascular regions of the CNS in normal
physiological and pathological states, and have been proposed to
migrate out of the CNS where they may act as APC in secondary
lymphoid organs. ‘‘New’’ brain antigens (foreign or modified self)
presented to the immune system during CNS inflammatory
disease states may not favor tolerance induction. Here, we first
detected a NT-modified protein with molecular mass ,20 kD
within the CLN of MPTP-treated mice, which was not observed in
any other lymphoid tissue examined. Later this NT-modified
protein was unambiguously identified as a-Syn by IP with N-a-Syn
specific antibody and in-gel tryptic digestion with protein
sequencing by LC MS/MS of the 12–18 kD band after 1D-SDS
PAGE. Several lines of evidence support the possibility of drainage
Figure 5. Adoptive transfer of SPC and purified T cells from N-4YSyn vaccinated B10.BR donors leads to infiltration of T cells in the SNpc of
MPTP mice on day 2. (A) Frequency of CD3
+ T cells and CD19
+ B cells before and after enrichment of T cells. Population of enriched T-cells was 94%
CD3
+ prior to adoptive transfer to B10.BR mice. (B) Sections throughout the SNpc were immunostained for CD3 and counterstained with thionin.
Clusters of CD3
+ cells are observed within the SNpc (arrowheads) as seen at 1006magnification (left). Magnification (600X) of boxed area (left panel)
is shown (right panel). CD3
+ cells are small and round exhibiting lymphocyte morphology.
doi:10.1371/journal.pone.0001376.g005
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PLoS ONE | www.plosone.org 13 January 2008 | Issue 1 | e1376of CNS antigens into the CLN. First, ovalbumin (OVA) antigen
directly injected into the striatum of mice resulted in antigen-
specific T cell education exclusively in the deep CLN [72]. Second,
in our model system, MBP, which is specific to the CNS, was also
identified by Western blot at the same time suggesting that brain-
derived antigens were draining to the CLN post-MPTP intoxica-
tion. Third, peroxynitrite favors nitration of Tyr residues on a-Syn
[73]. Two different strains of mice, B10.BR (H-2
k) and B6 (H-2
b),
expressing disparate MHC haplotypes were employed. Predictions
of MHC binding affinities for a-Syn T cell epitopes suggested an
increased number of peptides with intermediate and high degree
binding to class I MHC molecules of H-2
k, but not H-2
b.A n
overall stronger immunogenic binding potential even to MHC
class II was predicted for H-2
k when compared to H-2
b. These
predictions suggested the 2 strains would exhibit different levels of
T cell responses to N-a-Syn with consequential heterogeneous
outcomes affecting disease. It is not clear, whether in PD patients
the C-terminal fragment of a-Syn, which is nearly identical in mice
and human, is nitrated. However, earlier studies demonstrated
that monoclonal antibodies to N-a-Syn recognize fragments that
include nitrated Tyr
125 and Tyr
133 residues within a-Syn C-
terminal fragment [74]. Recent studies confirmed preference of
NT in close proximity to carboxylates [75]. This is consistent with
previous data that promote nitration of Tyr by nearby negative
charges [76]. Indeed, within the Tyr-containing 42 aa C-terminal
of a-Syn more than 28% (12 aa) are charged negatively
(Figure 3A). All together, we posit that monitoring of T cell
responses to epitopes predicted in this study may determine the
association of neurodegeneration and a-Syn immune responses.
The focus of the current study was to elucidate and characterize
new cellular and molecular mechanisms that explain the
prolonged neuroinflammation and progressive dopaminergic
neurodegeneration in PD as modeled by the administration of
MPTP. B10.BR or B6 mice immunized with the unmodified C-
terminal tail of a-Syn failed to generate detectable proliferative
responses after SPC were stimulated with 4YSyn or N-4YSyn, thus
suggesting a degree of tolerance to this self-protein. Conversely,
both strains of mice immunized with N-4YSyn developed robust
proliferative responses to the modified protein in vitro. Interestingly,
immune cells that recognized only the modified form did not
Figure 6. SPC from N-4YSyn immunized B10.BR mice exacerbate MPTP-induced dopaminergic neurodegeneration and induce microglial
responses in the SNpc. Photomicrographs from VMB sections stained with Fluoro-Jade C (left and middle panels) and Mac-1 antibody (right panels).
PBS controls (PBS/none) exhibit an absence of Fluoro-Jade C stained dead neurons on days 2 and 7, and only faint Mac-1 immunoreactivity on day 4
post-treatment. In MPTP-treated mice that received SPC from PBS/adjuvant treated donors (MPTP/PBS), Fluoro-Jade C stained neurons are evident at
day 2, but not detectable by day 7. MPTP-treated mice that received SPC from 4YSyn immunized donors (MPTP/4YSyn), also exhibits dead fluorescent
neurons by day 2 comparable to the MPTP/PBS control group, and only rare degenerating neurons are visible by day 7. Mac-1 immunoreactivity in
those mice is comparably resolved to levels seen in MPTP/PBS control group. SPC transfers from N-4YSyn immunized donors to MPTP-treated mice
(MPTP/N-4YSyn) induced a robust and prolonged microglial response, conspicuously enhanced when compared to MPTP/PBS-treated controls, with
concomitant neuronal death still evident by Fluoro-Jade C staining at day 7.
doi:10.1371/journal.pone.0001376.g006
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PLoS ONE | www.plosone.org 14 January 2008 | Issue 1 | e1376proliferate in response to the unmodified form suggesting a high
degree of specificity in generating adaptive immune responses to
the nitrated epitope. Exacerbation of dopaminergic neuronal loss
in both MPTP-intoxicated B6 and B10.BR mice that received N-
4YSyn immune cells from syngeneic donors was observed in our
studies. The loss of dopaminergic neurons within the SN of those
recipient mice was significantly greater compared to MPTP-
treated animals or those that received SPC from mice immunized
with 4YSyn or PBS. Transfer of SPC from mice immunized with
unmodified 4YSyn yielded no difference in SN dopaminergic
neuronal loss compared to those mice treated with MPTP alone.
Importantly, the transfer of purified T cells from N-4YSyn
immunized donors exacerbated nigral degeneration in B10.BR
mice. Elimination of adjuvant (CFA/IFA) from the immunization
strategy for B6 donors and subsequent adoptive transfer of N-
4YSyn immune SPC produced the most severe dopaminergic
neuronal losses. While behavioral testing of MPTP mice was
considered to substantiate dopaminergic neurodegeneration, those
Figure 7. N-4YSyn immunization with adjuvant exacerbates dopaminergic neuronal cell loss in B10.BR mice. (A) All panels show TH-positive
neurons in the SN from mice treated with: [top row, L to R] PBS or MPTP alone, MPTP and SPC from N-4YSyn immunized donors (MPTP+N-4YSyn),
[bottom row, L to R] PBS and SPC from N-4YSyn immunized donors (PBS+N-4YSyn), MPTP and SPC from 4YSyn immunized donors (MPTP+4YSyn), and
MPTP and T cells from N-4YSyn immunized donors (MPTP+N-4YSyn T Cells). Tissues collected 28 days post-MPTP treatment (B) Counts of nigral Nissl+
(blue bars), TH+ (red bars), and TH- (green bars) neurons on day 28 after MPTP treatment as determined by stereological analysis. Control groups
included mice treated with PBS alone (n=4), MPTP alone (n=8), and PBS animals that received immune effector SPC from N-4YSyn immunized donor
mice PBS/N-4YSyn/SPC (n=6). Experimental groups included MPTP/PBS/SPC (n=6), MPTP/4YSyn/SPC (n=8), MPTP/N-4YSyn/SPC (n=9), and MPTP
mice which received purified T cells from N-4YSyn vaccinated donors. Values are means 6 SEM. p,0.01 compared to the following treatment groups:
aPBS,
bMPTP,
cMPTP/4YSyn/SPC.
doi:10.1371/journal.pone.0001376.g007
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PLoS ONE | www.plosone.org 15 January 2008 | Issue 1 | e1376Figure 8. Scheme for immunization, lymphocyte proliferation assessment, and adoptive transfer of donor SPC in B6 mice. (A) B6 (H-2
b) mice
were immunized with 10 mg 4YSyn in PBS, 50 mg N-4YSyn in CFA, 10 mg N-4YSyn in PBS or PBS in CFA. Mice were boosted 14 days later with their
respective antigens as formulated previously with or without IFA. After 5 days, single lymphoid cell suspensions were prepared and assessed for
antigen-specific responses in standard lymphocyte proliferation assays. Single cell suspensions were pooled and adoptively transferred to MPTP-
treated syngeneic recipients 12 hrs after the final MPTP injection. 5610
7 donor immune SPC were adoptively transferred to MPTP-treated recipient
mice. Survival of dopaminergic neurons in the SN of recipient mice were evaluated after 7 days. (B) Antigen specific proliferation of SPC from B6 (H-
2
b) mice (n=5/group) immunized with PBS/CFA or N-4YSyn/CFA, and cultured for 5 days in media alone (green bars) or in the presence 1 mg/ml of
4YSyn (blue bars) or N-4YSyn (red bars). Cultures were pulsed for 18 hrs, cells harvested and
3H-thymidine incorporation counted by b-scintillation
spectrometry. Values represent mean stimulation indices6SEM and analyzed by ANOVA and Bonferroni post-hoc tests.
ap=0.0478.
doi:10.1371/journal.pone.0001376.g008
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PLoS ONE | www.plosone.org 16 January 2008 | Issue 1 | e1376were not performed as rodents do not develop typical parkinson-
ism and behavioral testing in MPTP mice has not proven to be
consistently reliable [77,78].
While the exact phenotype of the T cell response generated in
this vaccination strategy is unknown, a proinflammatory TH1
response was likely generated and associated with exacerbation of
inflammatory responses and neurotoxicity. We also demonstrated
in vitro that antigen-activated immune responses to N-4YSyn
augment N-4YSyn-induced, cell-mediated dopaminergic toxicity
with macrophages activated by N-a-Syn, linked to an induction of
TNF-a production by stimulated T cells. This suggests a potent
mechanism for exacerbation of inflammatory responses and
progression of dopaminergic neurodegenerative processes con-
ferred by N-4YSyn specific T cells. These data also emphasize
Figure 9. Lymphocytes from N-4YSyn immunization exacerbate nigral dopaminergic neuronal loss in B6 mice. (A) All panels show TH
+ neurons in
the SN from mice treated with PBS or MPTP alone, MPTP and SPC from 4YSyn immunized donors (MPTP+4YSyn), MPTP and SPC from N-4YSyn
immunized donors (MPTP+N-4YSyn) and lastly, MPTP and SPC from N-4YSyn+CFA immunized donors (MPTP+N-4YSyn CFA). (B) Counts of nigral TH
+
and TH
2 neurons on day 7 after MPTP treatment. Experimental groups included mice treated with PBS alone (n=7), MPTP alone (n=7), MPTP/4YSyn
(n=7), MPTP/N-4YSyn/CFA (n=6) and MPTP/N-4YSyn (n=6). Values are means 6 SEM. Analysis by ANOVA with Bonferroni post-hoc tests indicated
ap,0.0001 compared to PBS control:
bp,0.001 compared to MPTP group;
cp,0.001 compared to MPTP/4YSyn group; and
dp,0.03 compared to
MPTP/4YSynCFA SPC.
doi:10.1371/journal.pone.0001376.g009
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PLoS ONE | www.plosone.org 17 January 2008 | Issue 1 | e1376caution in design of vaccine-based therapeutic strategies for PD or
other neurodegenerative disorders. Recently, a promising Ab
vaccine strategy was employed in transgenic amyloid precursor
protein (APP) mice as a model for Alzheimer’s disease [79,80]. In
these studies, immunized APP transgenic animals showed
markedly reduced Ab deposition, preservation of normal neuronal
structures, and improved performance in memory and spatial
learning tasks. After completing a successful phase I trial with no
significant toxicities, phase II trials came to an abrupt end when 15
vaccine recipients experienced meningoencephalitis [81,82,83].
Clearly, immune system can generate T cell responses to proteins
that are similarly modified as those found in PD but alternative
routesofadministration maygenerate entirelydifferenteffectsonthe
disease process and as such do not preclude using these proteins as
potential vaccine candidates. For example, nasal administration
favors the generation of regulatory type TH2/TH3r e s p o n s e st o
antigens [84,85]. Mucosal vaccination using N-4YSyn may result in
dramatically different results than those presented here.
All together, we demonstrated for the first time, that NT a-Syn
modifications circumvent immunological tolerance. We posit that
these observations are directly relevant to the tempo and
progression of PD. Indeed, NT-modifications of a-Syn are present
in Lewy bodies during disease and when present in the
extracellular spaces of the brain appears in the CNL where a
robust adaptive immune response is produced that accelerates
Figure 10. N-4YSyn-mediated inhibition of T cell proliferation.
Proliferative responses of anti-CD3 stimulated T cells from naı ¨ve B6
mice in presence of graded concentrations of 4YSyn or N-4YSyn (1, 3,
10, 30 mg/ml) or in media alone (0 mg/ml). T cells were cultured for
72 hrs and pulsed with
3H-thymidine for the final 18 hrs of culture.
Harvested cells were counted for
3H-thymidine uptake by b-scintillation
spectrometry and proliferation was expressed as mean counts per min
(CPM)6SEM for quadruplicate samples and evaluated by ANOVA with
Bonferroni post-hoc tests.
ap,0.01 compared with T cells stimulated
with anti-CD3 and cultured in media alone.
doi:10.1371/journal.pone.0001376.g010
Table 4. N-4YSyn-induced cytotoxicity of stimulated T cells.
......................................................................
aT Cell
Treatment
Conc.
mg/ml
bPercent PI
+
T Cells
cMFI
dD
eIndex of
Similarity
Medium 5.7 33.0 * 0
4YSyn 1 4.9 32.2 0.08 3.8
3 6 34.1 0.08 4.2
10 4.7 25.2 0.1 5.1
30 4.2 26.8 0.16 8.1
N-4YSyn 1 15.9 42.8 0.31 15.7
3 17.9 58.7 0.33 15.6
10 47.8 71.6 0.64 30.9
30 91.3 106.1 0.87 43.4
aAnti-CD3 stimulated T cells were cultured for 24 hrs in media alone or in the
presence of different concentrations of 4YSyn or N-4YSyn, stained with 2 mg/
ml of the vital dye, PI, washed, and assessed by flow cytometric analysis for
uptake of PI.
bPercentage of T cells susceptible to PI permeation as determined by flow
cytometric analysis.
cMean fluorescence intensity of PI-stained T cells.
dD statistic at a=0.001 of Kolmogorov-Smirnov (K-S) analysis for fluorescence
intensities of PI-stained T cells as the sigmoidal function of the accumulated
cell frequency curve and fluorescence intensity (channel number) compared to
the curve of PI-stained T cells from the medium control (asterisk) as computed
by Cellquest software (BD Biosciences) [88].
eIndex of similarity=D/[(nc+nt)/(nc?nt)]
1/2, where nc and nt are the number of
events in cell frequency curves for medium control (c) and test substance (t),
respectively (BD Biosciences) [88]. An index of similarity=0 indicates the curves
are identical.
doi:10.1371/journal.pone.0001376.t004
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Figure 11. N-4YSyn activated immune SPC induces macrophage-
mediated dopaminergic cell death. Representative fluorescence
photomicrographs are shown of live (green) and dead (red) cells from
24 hr macrophage/MES 23.5 co-cultures in the presence of media alone,
N-4YSyn, N-4YSyn and antigen-stimulated SPC of N-4YSyn-immunized
mice (N-4YSyn+SPC), or N-4YSyn and the supernatants from antigen-
stimulated SPC of N-4YSyn-immunized mice (N-4YSyn+SPC Sup).
Antigen-stimulated SPC from N-4YSyn immune mice were induced in
vitro with N-4YSyn, and cells and supernatants for use in the assay were
harvested after 5 days of culture. Controls included macrophages
cultured in the presence of SPC supernatants from antigen-stimulated
SPC of N-4YSyn-immunized mice (Macrophages+SPC Sup); macrophag-
es cultured in the presence of N-4YSyn alone (Macrophages+N4YSyn);
and transwell cultures of plated MES 23.5 cells and macrophages in the
transwell stimulated with N-4YSyn. Frequencies (6SEM) of dead (red)
cells for 4-8 fields/assay are provided in the lower right corner of each
panel. Differences in the mean frequencies of dead cells were evaluated
by ANOVA and Bonferroni post-hoc tests. p,0.01 compared to cultures
treated with
aMedia,
bN-4YSyn, or
cN-4YSyn+SPC.
doi:10.1371/journal.pone.0001376.g011
Immunity and Neurodegeneration
PLoS ONE | www.plosone.org 18 January 2008 | Issue 1 | e1376nigral dopaminergic neuronal degeneration. Most importantly the
abilities of N-a-Syn to evade immunological tolerance provides a
novel pathogenic mechanism for PD and new opportunities for
therapeutic intervention.
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